Drug intelligence / Profile preview

GP-61

Development stage: Preclinical
Lead developer: GliaPharm
Modality: Small Molecules

Overview

GP-61 is a preclinical drug candidate series developed by GliaPharm. It is designed to address a novel, undisclosed molecular target within astrocytes. GliaPharm's core technology focuses on modulating metabolic pathways in glial cells to increase the energy available to the brain, aiming to treat neurological and psychiatric disorders characterized by deficient brain energetics. As of the current pipeline status, GP-61 is in the discovery or preclinical development phase, utilizing the company's GliaX platform to identify and optimize compounds that restore brain metabolic homeostasis.

Beyond the preview

Go deeper on GP-61.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GP-61.

Explore the full profile